MIRA PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $1.7M | $3.3M | $1.6M | $2.4M | — |
| Operating expenses | $10.5M | $8.0M | $8.5M | $7.0M | — |
| Interest expense | — | $165,669 | $3.5M | $10,250 | — |
| Net income | -$10.4M | -$7.9M | -$12.0M | -$7.1M | — |
| Balance Sheet | |||||
| Cash and equivalents | $6.3M | $2.8M | — | — | — |
| Current assets | $11.1M | $2.9M | $4.9M | $494,405 | — |
| Total assets | $11.1M | $2.9M | $4.9M | $858,074 | — |
| Current liabilities | $702,068 | $723,349 | $558,097 | $1.4M | — |
| Total liabilities | $702,068 | $723,349 | $558,097 | $1.5M | — |
| Stockholders' equity | $10.4M | $2.2M | $4.4M | -$596,232 | $2.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$4.7M | -$5.6M | -$4.5M | -$5.6M | — |
| Stock-based compensation | $6.3M | $1.9M | $2.6M | $1.3M | — |
Shares outstanding 42.0M · Free float 70.2%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.